Pharmacokinetic Response to BPI in Burns

Phase 2 Terminated 4 enrolled University of Texas Southwestern Medical Center

NaSingle-groupOpen-labelTreatment

Summary

The purpose of this study is to evaluate the safety of a protein called BPI that is naturally made by the body's white blood cells to fight infection.

Timeline

Start: 2006-04
Primary completion: 2007-11
Completion: 2007-11

Outcome

Outcome not reported

Stopped: “Xoma to no longer supply drug for the study”

Drugs

Evaluation	Drug	Modality	Dose	Route
Subject	BPI	Protein / enzyme biologic	—	Intravenous

Indications

No indication recorded.